Coherus looks to disrupt Amgen’s $4B Neulasta franchise as analysts look for a deep discount on its copycat price
Despite being the runner-up in the race to a US approval for a biosimilar of Neulasta, analysts are watching to see if little Coherus could gain quick traction if they sell theirs at a big discount to Mylan’s rival.
On Friday, Coherus said it had secured the FDA’s nod for a copycat version of Amgen’s blockbuster product — coming second to Mylan $MYL and Indian partner Biocon in the race to market a biosimilar for Neulasta in the more lucrative US market. Coherus’ biosimilar, Udencya, was granted European approval in September.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.